West Pharmaceutical
WST
West Pharmaceutical (WST) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $2.37
- EPS estimate
- $2.08
- EPS surprise
- +13.86%
- Revenue surprise
- +3.85%
- Revenue
- $872.3M
- Revenue estimate
- $840.0M
- Reported
- Jul 23, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 23, 2026 | $2.08 | $2.37 | +13.86% | $872.3M | SEC |
| Q1 2026 | Apr 23, 2026 | $1.68 | $2.13 | +26.94% | $844.9M | SEC |
| Q4 2025 | Feb 12, 2026 | $1.83 | $2.04 | +11.62% | $805.0M | SEC |
| Q3 2025 | Oct 23, 2025 | $1.68 | $1.96 | +16.33% | $804.6M | SEC |
| Q2 2025 | Jul 24, 2025 | $1.51 | $1.84 | +21.92% | $766.5M | SEC |
| Q1 2025 | Apr 24, 2025 | $1.23 | $1.45 | +18.13% | $698.0M | SEC |
| Q4 2024 | Feb 13, 2025 | $1.72 | $1.82 | +5.87% | $748.8M | SEC |
| Q3 2024 | Oct 24, 2024 | $1.50 | $1.85 | +23.28% | $746.9M | SEC |
| Q2 2024 | Jul 25, 2024 | $1.74 | $1.52 | −12.70% | $702.1M | SEC |
| Q1 2024 | Apr 25, 2024 | $1.27 | $1.56 | +22.51% | $695.4M | SEC |
| Q4 2023 | Feb 15, 2024 | $1.78 | $1.83 | +2.91% | $732.0M | SEC |
| Q3 2023 | Oct 26, 2023 | $1.86 | $2.16 | +16.34% | $747.4M | SEC |
| Q2 2023 | Jul 27, 2023 | $1.93 | $2.11 | +9.53% | $753.8M | SEC |
| Q1 2023 | Apr 27, 2023 | $1.67 | $1.98 | +18.68% | $716.6M | SEC |
| Q4 2022 | Feb 16, 2023 | $1.38 | $1.77 | +28.66% | $708.7M | SEC |
| Q3 2022 | Oct 27, 2022 | $2.12 | $2.03 | −4.25% | $686.9M | SEC |
| Q2 2022 | Jul 28, 2022 | $2.21 | $2.47 | +11.89% | $771.3M | SEC |
| Q1 2022 | Apr 28, 2022 | $2.12 | $2.30 | +8.32% | $720.0M | SEC |
| Q4 2021 | Feb 17, 2022 | $1.92 | $2.04 | +6.50% | $730.8M | SEC |
| Q3 2021 | Oct 28, 2021 | $1.80 | $2.06 | +14.65% | $701.0M | SEC |
Quarterly revenue
Frequently asked questions
When did West Pharmaceutical (WST) last report earnings?
West Pharmaceutical last reported on Jul 23, 2026, covering fiscal Q2 2026.
Did WST beat earnings estimates?
Yes. West Pharmaceutical reported EPS of $2.37 for Q2 2026 against a $2.08 estimate — a 13.86% beat.
How much revenue did WST report last quarter?
West Pharmaceutical reported $872.3M in revenue for Q2 2026, against a consensus estimate of $840.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.